Genmab — Juni 2020
-
Genmab price target raised to $34 from $29 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $34 from $29 and reiterates a Buy rating on the shares. The company last week announced positive top-line results for the combination of subcutaneous Darzalex plus cyclophosphamide, bortezomib and dexamethasone versus CyBorD alone from the Phase 3 ANDROMEDA trial, Selvaraju tells investors in a research note
The Fly | LANDING
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
-
God morgen.
-
God morgen
-
Jan er på i eftermiddag 14.30 CET. https://ir.genmab.com/events-and-presentations
-
Amerikansk finanshus følger efter UBS: Hæver kursmål på Genmab-aktien til 2500 kr https://borsen.dk/nyheder/virksomheder/citi-oger-kursmaal-for-genmab-med-56-pct-til-2500-kr#
-
Ifølge Citi er de mest oplagte kandidater til et partnerskab at finde mellem medicinalkoncerne Abbvie, Astazeneca, Johnson & Johnson samt Novartis, hvor Genmab allerede har partnerskaber med de to sidstnævnte.
Peter Verdult tror dog, at de førstnævnte er mere oplagte til dette middel.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind